« Return to News | R&D Trends

Wilex, Nuclea Biotechnologies form partnership

Wednesday, March 20, 2013 10:08 AM

Pittsfield, Mass-based biomarker pioneer Nuclea Biotechnologies has formed a new long-term partnership with biopharmaceutical company Wilex, which could lead to more effective treatment management for women with metastatic breast cancer. The partnership aims to advance R&D of biomarkers, a vital component in the growing field of personalized medicine. 

In April, the clinical testing will begin in Nuclea’s newly designed, state of the art laboratory in Pittsfield, and will result in the addition of three new employees. The partnership between Nuclea and Wilex will allow oncologists greater access, through Nuclea’s laboratory, to the ELISA test to measure the HER-2/neu level in the serum portion of blood.

"Nuclea is excited about the new partnership," said Patrick J. Muraca, president and CEO of Nuclea. "Both companies seek to develop new biomarkers with the goal of making 21st century cancer treatments more personal and effective. With our combined experience in the production and commercialization of biomarkers, it seemed very natural for us to work together as pioneers in the field of breast cancer."

Olaf G. Wilhelm, CEO of Wilex, added, "Since Nuclea understands and focuses on gene and protein expression profiles in tumors, the serum HER-2 test is an important addition to their profiling efforts. Besides using our HER-2 ELISA in its CLIA lab, Nuclea will also start R&D and validation of this test in early breast cancer and possibly other indications."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.